Literature DB >> 19663114

Alopecia areata treated with efalizumab: a case with significant hair re-growth after long-term therapy.

Jeffrey R Smith1, Russell S Akin, Michael J Wells.   

Abstract

Efaluzimab has recently been described as a treatment for alopecia areata. Conflicting reports and studies have spurred discussion as to whether efaluzimab is an effective treatment of alopecia areata. Proposed mechanisms for this immune-modifying agent have suggested that efficacy is derived from efaluzimab's effects on T cells. However, a recent molecular study found no alteration in T cell action around hair follicles at six months of treatment and thus the study concluded that efaluzimab was not an effective treatment. This article describes a nine-year-old male with recalcitrant alopecia totalis for seven years who had been nonresponsive to therapeutic intervention. He was started on efaluzimab for severe atopic dermatitis and began to re-grow scalp hair at one year of treatment. This discussion suggests that longer treatment durations may be needed for treatment effects to be seen in some patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19663114

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  2 in total

1.  Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata

Authors:  Zekayi Kutlubay; Ayşegül Sevim; Övgü Aydın; Suphi Vehid; Server Serdaroğlu
Journal:  Turk J Med Sci       Date:  2020-12-17       Impact factor: 0.973

Review 2.  Alopecia Areata: An Autoimmune Disease of Multiple Players.

Authors:  Poonkiat Suchonwanit; Chaninan Kositkuljorn; Cherrin Pomsoong
Journal:  Immunotargets Ther       Date:  2021-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.